Products Overview

molecularimaging

TRIPLE THREAT TECHNOLOGY

Enlyton has developed ENL210 (an anti-TAG-72 humanized monoclonal antibody fragment) as a cancer-specific targeting agent for:

1. SPECT/CT imaging

2. Intraoperative imaging

3. Intraoperative detection.

Enlyton expects to enter clinical trials with ENL210 in early 2017.